# An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

> **NCT03882918** · PHASE3 · TERMINATED · sponsor: **Healx AI** · enrollment: 141 (actual)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** OV101

## Key facts

- **NCT ID:** NCT03882918
- **Lead sponsor:** Healx AI
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-31
- **Primary completion:** 2021-06-04
- **Final completion:** 2021-06-30
- **Target enrollment:** 141 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03882918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03882918, "An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03882918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*